OVERVIEW

CJC‑1295 (no DAC) + Hexarelin 10 mg (Blend) is a research peptide combination studied in laboratory and preclinical contexts for its potential to influence the growth hormone (GH) axis. CJC‑1295 (no DAC) is an analog of growth hormone‑releasing hormone (GHRH) designed to bind the GHRH receptor on pituitary somatotroph cells, stimulating release of endogenous GH. Without a drug affinity complex (DAC), this version has a relatively short half‑life, encouraging pulsatile GH secretion that more closely mimics natural hormonal rhythms. Hexarelin is a synthetic growth hormone secretagogue that targets the GHS‑R1a (ghrelin) receptor, triggering additional GH release through a distinct pathway. Because CJC‑1295 and Hexarelin act on separate receptors — one at the hypothalamic/pituitary axis and the other at the ghrelin receptor — combining them in a blend is thought in research settings to potentially produce additive or synergistic stimulation of GH pulses, which researchers use to explore GH regulation, metabolism, and cellular responses to elevated GH levels in controlled experiments.

Despite scientific interest, this peptide blend is not approved for therapeutic use by the U.S. Food and Drug Administration or equivalent regulatory bodies. Most data supporting its biological effects come from animal studies, cell culture experiments, or small uncontrolled observations rather than rigorous human clinical trials demonstrating safety, efficacy, or appropriate dosing. Products marketed with these peptides are usually labeled for research use only, and their purity, quality, and dosing consistency can vary widely between sources. Because of these uncertainties, self‑administration outside of properly controlled research environments is not recommended, and individuals should consult qualified healthcare professionals for evidence‑based approaches to hormone or metabolic health.